-
The State Food and Drug Administration conditionally approved the marketing of Linplisset tablets
Time of Update: 2023-01-06
The listing of this drug provides a treatment option for adult patients with relapsed and refractory follicular lymphoma after treatment with existing treatments.
The listing of this drug provides a treatment option for adult patients with relapsed and refractory follicular lymphoma after treatment with existing treatments.
-
The State Food and Drug Administration conditionally approved the marketing of Linplisset tablets
Time of Update: 2023-01-06
The listing of this drug provides a treatment option for adult patients with relapsed and refractory follicular lymphoma after treatment with existing treatments.
The listing of this drug provides a treatment option for adult patients with relapsed and refractory follicular lymphoma after treatment with existing treatments.
-
Research frontier| efficacy of EphB2 inhibitors combined with PD-1 monoclonal antibody in mUC
Time of Update: 2022-11-05
GuideBladderurothelial carcinoma is a common tumor in urology, and the 5-year survival rate of newly diagnosed patients is low, while the median survival of patients after first-line platinum-based chemotherapy is about 1 year, and the prognosis is poor.
-
The listing application of Chia Tai Tianqing TQ-B3101 capsules was accepted
Time of Update: 2022-08-15
. TQ-B3101 is a novel small molecule receptor tyrosine kinase inhibitor targeting ALK/ROS1/MET .
. TQ-B3101 is a novel small molecule receptor tyrosine kinase inhibitor targeting ALK/ROS1/MET .
Preclinical studies have shown that the drug has good antitumor activity and duration of efficacy .
-
The CREB binding protein (CBP)/β-catenin inhibitor E7386 jointly developed by Eisai and PRISM BioLab achieved clinical POC (proof of concept
Time of Update: 2021-12-02
Based on the results of the POC, Eisai initiated a phase Ib/II clinical trial of E7386 combined with anti-PD-1 therapy pembrolizumab in the treatment of solid tumors (Study 201) in Japan .
-
JAMA Sub-Journal: The relationship between SGLT2 inhibitors and the incidence of type 2 diabetes and gout
Time of Update: 2021-12-02
Sodium - glucose transporter (the SGLT2) 2 using an inhibitor is 2 type diabetes mellitus (T2DM) standard interventions the patient has good pleiotropic effects on lowering blood uric acid levels continued .
-
The cancer-free survival period is two years long! Chinese innovative drug targeted adjuvant treatment of lung cancer
Time of Update: 2021-09-06
The EVIDENCE study showed that after radical surgery in patients with stage II-IIIA EGFR-mutant NSCLC, compared with standard adjuvant chemotherapy, adjuvant therapy with icotinib significantly prolonged disease-free survival (DFS) and was better tolerated .
-
NEJM: Upadacitinib is better than adalimumab in treating psoriatic arthritis
Time of Update: 2021-04-13
Researchers have recently launched the SELECT-PsA 1 study to evaluate the efficacy and safety of Upadacitinib treatment in patients with psoriatic arthritis who have not responded to or are intolerant to traditional antirheumatic drug treatments.
For patients with psoriatic arthritis, Upadacitinib treatment was better than placebo in terms of ACR20 response at week 12.
-
The European Union approved Tukysa for the treatment of HER2-positive localized advanced or metastasis breast cancer
Time of Update: 2021-02-25
in the HER2CLIMB trial at Tukysa in Seagen, TKI and cratur bead monoantigen and carpedabin used to reduce the risk of disease progress in patients by 46%.
survival of patients in the Tukysa combined treatment group was also improved, with a 34 percent reduction in the risk of death.
-
Beda Pharmaceuticals to issue "H shares
Time of Update: 2021-02-01
A few days ago, Beda Pharmaceuticals announced that the company has considered the adoption of the "on the company's H-share issue and listing on the main board of the Stock Exchange of Hong Kong Lim
-
The Design, Annotation, and Application of a Kinase-Targeted Library
Time of Update: 2020-12-21
To further assist kinase projects in triaging KTL screen hits, we also developed a methodology to systematically annotate known kinase inhibitors in the KTL with regard to their binding modes.
-
Clini Cancer Research: New BTK inhibitor Zanubrutinib treatment recurrent/refractive MCL
Time of Update: 2020-07-13
Objective: Set cell lymphoma (MCL) is an incurable mature B-cell tumor with a high initial remission rate, but most cases tend to recur The prognosis of patients with recurrence is poor and treatm
-
Lancet: Acalabrutinib's first-line treatment of chronic lymphocytic leukemia is effective
Time of Update: 2020-06-25
Acalabrutinib is an alternative Bruton tyrosine kinase inhibitor that has the activity to treat chronic lymphocytic leukemia The researchers looked at the efficacy of Acalabrutinib in the treatment
-
Blueprint's application for new drug from Avapritinib is accepted by FDA
Time of Update: 2020-06-08
recently, Blueprint announced (http:// that the u.S FDA (http:// has accepted the company's application for new drug (http:// (NDA) for treatment of adult patients with PDGFRA exosomes with
-
Puma Biotechnology's Nerinib approved for extended complementary treatment for early stage breast cancer patients
Time of Update: 2020-06-08
recently, the (http:// of the http:// announced by the of the http:// of medicines and, the argentine Medicines (http:// , food and medical device s (http:// Agency has approved Nerlynx for
